<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors 	</title>
	<atom:link href="https://www.newpharmaitaly.it/dragonfly-therapeutics-initiates-phase-1-2-study-of-its-il12-immunotherapy-in-patients-with-advanced-solid-tumors/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/dragonfly-therapeutics-initiates-phase-1-2-study-of-its-il12-immunotherapy-in-patients-with-advanced-solid-tumors/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Tue, 21 Jul 2020 11:00:40 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.1</generator>
</channel>
</rss>
